Medicenna Therapeutics Corp. (TSX: MDNA)

Medicenna Therapeutics Income Statement

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Selling, General & Admin	6.98	7.87	7	7.76	6.53	2.38
Research & Development	11.36	10.8	9.3	14.72	10.87	5.87
Operating Expenses	18.35	18.67	16.3	22.47	17.4	8.25
Operating Income	-18.35	-18.67	-16.3	-22.47	-17.4	-8.25
Interest & Investment Income	1.22	1.2	0.91	0.07	0.31	0.01
Currency Exchange Gain (Loss)	-0.14	-0.07	1.65	-0.17	-0.21	-0.04
Other Non Operating Income (Expenses)	-9.41	-7.92	3.7	-	-	-
EBT Excluding Unusual Items	-26.68	-25.47	-10.05	-22.58	-17.29	-8.28
Pretax Income	-26.68	-25.47	-10.05	-22.58	-17.29	-8.28
Net Income	-26.68	-25.47	-10.05	-22.58	-17.29	-8.28
Net Income to Common	-26.68	-25.47	-10.05	-22.58	-17.29	-8.28
Shares Outstanding (Basic)	72	70	65	54	50	32
Shares Outstanding (Diluted)	72	70	65	54	50	32
Shares Change (YoY)	4.04%	7.57%	19.25%	9.31%	55.68%	24.25%
EPS (Basic)	-0.37	-0.37	-0.16	-0.42	-0.35	-0.26
EPS (Diluted)	-0.37	-0.37	-0.16	-0.42	-0.35	-0.26
Free Cash Flow	-16.85	-16.26	-12.66	-23.58	-15.31	-5.42
Free Cash Flow Per Share	-0.23	-0.23	-0.20	-0.43	-0.31	-0.17
EBITDA	-18.33	-18.67	-16.3	-22.44	-17.36	-8.24
D&A For EBITDA	0.01	0	0	0.04	0.04	0.01
EBIT	-18.35	-18.67	-16.3	-22.47	-17.4	-8.25

Source: S&P Capital IQ. Standard template. Financial Sources.